

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in this application:

**Listing of Claims:**

Claims 1-17. (Cancelled)

18. (Previously amended) A method of treating a coagulation disorder in a patient having an atherosclerotic plaque comprising administering to the patient a therapeutically effective amount of ~~a~~ lipoprotein associated coagulation inhibitor ("LACI").

19. (Previously added) The method according to claim 18, further comprising administering a thrombolytic agent to the patient.

20. (Previously added) The method according to claim 19, wherein the thrombolytic agent is selected from the group consisting of a streptokinase, urokinase, prourokinase and a tissue-type plasminogen activator.

21. (Currently amended) The method according to claim 19, wherein the LACI is given at a dose of ~~about~~ in the range of 0.01-25.0 mg per kg of patient weight and the thrombolytic agent is given at a dose of ~~about~~ in the range of 0.01-2.5 mg per kg of patient weight.

22. (Previously added) The method according to claim 18 wherein the administration is by bolus.

SEE  
EXAMINER'S  
1mo  
6/27/05  
M

USPN 09/924,857

23. (Currently amended) The method according to claim 18 wherein the administration is by ~~the intravenous~~ intravenous infusion.

Claim 24-25. (Cancelled)

26. (Previously added) The method according to claim 18 wherein the patient is a human.